Quick Answer
Korro Bio, Inc. reported Net Income Loss of -$117.26 million for the year ending 2025.
- Korro Bio, Inc. showed a decrease of -40.3% in Net Income Loss from 2024 to 2025.
- This data is from Korro Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$4.15 million | Q2 2018: -$4.44 million | Q3 2018: -$5.14 million | Q4 2018: -$5.45 million | Q1 2019: -$5.83 million | Q2 2019: -$6.85 million | Q3 2019: -$575.0 thousand | Q4 2019: -$5.49 million | Q1 2020: -$4.91 million | Q2 2020: -$6.03 million | Q3 2020: -$5.34 million | Q4 2020: -$10.23 million | Q1 2021: -$20.38 million | Q2 2021: -$17.66 million | Q3 2021: -$25.16 million | Q1 2022: -$23.39 million | Q2 2022: -$21.29 million | Q3 2022: -$19.55 million | Q1 2023: -$19.61 million | Q2 2023: -$17.65 million | Q3 2023: -$18.49 million | Q1 2024: -$19.56 million | Q2 2024: -$21.83 million | Q3 2024: -$21.00 million | Q1 2025: -$23.39 million | Q2 2025: -$25.77 million | Q3 2025: -$18.06 million.
- Over the full 9 years of available data (2017 to 2025), Korro Bio, Inc.'s Net Income Loss has declined by 479.4%.
- Historical annual values: Fiscal year 2025: -$117.26 million | Fiscal year 2024: -$83.58 million | Fiscal year 2023: -$81.17 million | Fiscal year 2022: -$58.03 million | Fiscal year 2021: -$84.69 million | Fiscal year 2020: -$26.51 million | Fiscal year 2019: -$18.75 million | Fiscal year 2018: -$19.17 million | Fiscal year 2017: -$20.24 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: